Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1981 1
1982 2
1983 3
1984 3
1985 8
1986 7
1987 9
1988 9
1989 8
1990 18
1991 20
1992 13
1993 14
1994 20
1995 16
1996 16
1997 14
1998 15
1999 19
2000 24
2001 31
2002 26
2003 25
2004 36
2005 49
2006 61
2007 77
2008 80
2009 99
2010 98
2011 130
2012 155
2013 171
2014 175
2015 204
2016 214
2017 236
2018 253
2019 278
2020 355
2021 366
2022 467
2023 480
2024 129

Text availability

Article attribute

Article type

Publication date

Search Results

3,979 results

Results by year

Filters applied: . Clear all
Page 1
Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity.
Cao Y, Li Y, Wang X, Liu S, Zhang Y, Liu G, Ye S, Zheng Y, Zhao J, Zhu X, Chen Y, Xu H, Feng D, Chen D, Chen L, Liu W, Zhou W, Zhang Z, Zhou P, Deng K, Ye L, Yu Y, Yao Z, Liu Q, Xu H, Zhou J. Cao Y, et al. Among authors: feng d. Immunity. 2023 Feb 14;56(2):320-335.e9. doi: 10.1016/j.immuni.2022.12.017. Epub 2023 Jan 23. Immunity. 2023. PMID: 36693372
Migrasomes, a new mode of intercellular communication.
Jiang Y, Liu X, Ye J, Ma Y, Mao J, Feng D, Wang X. Jiang Y, et al. Among authors: feng d. Cell Commun Signal. 2023 May 8;21(1):105. doi: 10.1186/s12964-023-01121-4. Cell Commun Signal. 2023. PMID: 37158915 Free PMC article. Review.
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Zhu HD, et al. Among authors: feng dp. Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0. Signal Transduct Target Ther. 2023. PMID: 36750721 Free PMC article.
3,979 results